Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020. RESULTS Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29–0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively. CONCLUSIONS In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.

[1]  A. Crisanti,et al.  Author Correction: Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ , 2021, Nature.

[2]  Oliver Schnell,et al.  Issues for the management of people with diabetes and COVID-19 in ICU , 2020, Cardiovascular Diabetology.

[3]  F. Mauvais-Jarvis.  Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19 , 2020, Diabetes.

[4]  M. Gorrell.  Faculty Opinions recommendation of Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[5]  S. Bhatt,et al.  Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ , 2020, Nature.

[6]  S. Bhatt,et al.  Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ , 2020, Nature.

[7]  P. Fiorina,et al.  Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 , 2020, Acta Diabetologica.

[8]  F. Martinez,et al.  Severe Covid-19. , 2020, The New England journal of medicine.

[9]  Anlin Peng,et al.  Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication , 2020, Diabetes Care.

[10]  Jianhong Lu,et al.  The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike , 2020, iScience.

[11]  G. Remuzzi,et al.  Adaptations and Lessons in the Province of Bergamo , 2020, The New England journal of medicine.

[12]  Fang Lei,et al.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[13]  P. Pozzilli,et al.  DPP4 inhibition: Preventing SARS‐CoV‐2 infection and/or progression of COVID‐19? , 2020, Diabetes/metabolism research and reviews.

[14]  C. Signorelli,et al.  COVID-19 deaths in Lombardy, Italy: data in context , 2020, The Lancet Public Health.

[15]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[16]  D. Drucker.  Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications , 2020, Endocrine reviews.

[17]  Huihui Ren,et al.  Clinical characteristics and outcomes of patients with severe covid-19 with diabetes , 2020, BMJ Open Diabetes Research & Care.

[18]  A. Avogaro,et al.  Prevalence and impact of diabetes among people infected with SARS-CoV-2 , 2020, Journal of Endocrinological Investigation.

[19]  G. Iacobellis.  COVID-19 and diabetes: Can DPP4 inhibition play a role? , 2020, Diabetes Research and Clinical Practice.

[20]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[21]  G. Remuzzi,et al.  COVID-19 and Italy: what next? , 2020, The Lancet.

[22]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[23]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[24]  Shuye Zhang,et al.  Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses , 2020, bioRxiv.

[25]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[26]  G. Zuccotti,et al.  Sitagliptin favorably modulates immune-relevant pathways in human beta cells. , 2019, Pharmacological research.

[27]  Jennifer K. Sun,et al.  A Signature of Circulating Inflammatory Proteins and Development of End Stage Renal Disease in Diabetes , 2019, Nature Medicine.

[28]  C. Mantzoros,et al.  Beyond glycemic control: New guidance on cardio-renal protection. , 2019, Metabolism: clinical and experimental.

[29]  C. Deacon.  Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes , 2019, Front. Endocrinol..

[30]  D. Drucker,et al.  Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. , 2019, Cell metabolism.

[31]  E. Clementi,et al.  The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis , 2018, Acta Diabetologica.

[32]  R. Gorjão,et al.  Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Yan Li,et al.  DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation , 2017, Endocrine.

[34]  P. Fiorina,et al.  Type 1 Diabetes and Dysfunctional Intestinal Homeostasis , 2016, Trends in Endocrinology & Metabolism.

[35]  H. Lebovitz,et al.  Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas , 2016, Diabetes, obesity & metabolism.

[36]  D. Nathan.  Diabetes: Advances in Diagnosis and Treatment. , 2015, JAMA.

[37]  Robert R. Henry,et al.  Type 2 diabetes mellitus , 2015, Nature Reviews Disease Primers.

[38]  C. Mameli,et al.  Explaining the increased mortality in type 1 diabetes. , 2015, World journal of diabetes.

[39]  H. Yanai.  Dipeptidyl peptidase-4 inhibitor sitagliptin significantly reduced hepatitis C virus replication in a diabetic patient with chronic hepatitis C virus infection. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[40]  M. Rastaldi,et al.  Role of podocyte B7-1 in diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[41]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[42]  P. Dandona,et al.  Sitagliptin exerts an antinflammatory action. , 2012, The Journal of clinical endocrinology and metabolism.

[43]  A. Corsini,et al.  Pharmacology of Dipeptidyl Peptidase-4 Inhibitors , 2011, Drugs.

[44]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[45]  W. Zeng,et al.  Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses , 2005, Clinical pharmacology and therapeutics.

[46]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[47]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[48]  K. Yarasheski,et al.  A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection , 2019 .